NervGen Pharma Corp
NervGen Pharma Corp is a clinical-stage biotech company focused on developing innovative treatments to enable nervous system repair in cases of traumatic injury and disease. Their lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for spinal cord injury, with additional preclinical evaluations for conditions such as ischemic stroke and amyotrophic lateral sclerosis (ALS). The company is also advancing a new development candidate, NVG-300, in preclinical studies.
Industries
Nr. of Employees
small (1-50)
NervGen Pharma Corp
112-970 Burrard Street, Unit 1290, Vancouver, BC V6Z 2R4
Awards
Military Prototype Advancement Initiative (MPAI)
Evaluation of NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following Peripheral Nerve Injury
Funding (ceiling)
$1,470,424.92
Award Year
2022
Products
Clinical-stage neuroreparative peptide candidate (spinal cord injury)
Clinical-stage peptide therapeutic candidate evaluated in a Phase 1b/2a proof-of-concept study for chronic and acute spinal cord injury using functional and electrophysiological endpoints.
Preclinical neuroreparative peptide candidate (ischemic stroke)
Preclinical-stage peptide therapeutic candidate evaluated in ischemic stroke and confirmatory spinal cord injury models to assess functional recovery and neural repair mechanisms.
Clinical-stage neuroreparative peptide candidate (spinal cord injury)
Clinical-stage peptide therapeutic candidate evaluated in a Phase 1b/2a proof-of-concept study for chronic and acute spinal cord injury using functional and electrophysiological endpoints.
Preclinical neuroreparative peptide candidate (ischemic stroke)
Preclinical-stage peptide therapeutic candidate evaluated in ischemic stroke and confirmatory spinal cord injury models to assess functional recovery and neural repair mechanisms.
Expertise Areas
- Early-stage clinical trial management (Phase 1 / Phase 1b–2a)
- Mechanism-driven neuroreparative therapeutic development
- Translational research and preclinical-to-clinic translation
- Biomarker and neurophysiological outcome development
Key Technologies
- Intracellular peptide therapeutics
- Preclinical animal models (rodent and large-animal)
- Electrophysiology and neuroconnectivity assessment
- Quantitative MRI and imaging-based outcome measures
Key People
News & Updates
NervGen reported its financial and operational results for the third quarter ended September 30, 2024, including updates on the Phase 1b/2a clinical trial of NVG-291.
NervGen announced that target enrollment of the chronic cohort in its Phase 1b/2a clinical trial for NVG-291 in individuals with spinal cord injury is approaching completion.
NervGen reported its financial and operational results for the second quarter ended June 30, 2024, including advancements in the clinical development of NVG-291 and the initiation of NVG-300.
NervGen reported its financial and operational results for the third quarter ended September 30, 2024, including updates on the Phase 1b/2a clinical trial of NVG-291.
NervGen announced that target enrollment of the chronic cohort in its Phase 1b/2a clinical trial for NVG-291 in individuals with spinal cord injury is approaching completion.
NervGen reported its financial and operational results for the second quarter ended June 30, 2024, including advancements in the clinical development of NVG-291 and the initiation of NVG-300.